Please check your internet connection and try again.
# Flupentixol and Melitracen
## Overview
Flupentixol is a typical antipsychotic of the thioxanthene class. Melitracen is a tricyclic antidepressant (TCA). This combination is used for the treatment of anxiety and depression.
## Primary Indications
* Anxiety and depressive states.
* Psychosomatic disorders.
## Adult Dosing
* **Standard Dosing:** 1 tablet (containing 0.5 mg flupentixol and 10 mg melitracen) twice daily (morning and noon).
* **Increased Dosing:** May be increased to 2 tablets (containing 0.5 mg flupentixol and 10 mg melitracen) twice daily upon tolerance and therapeutic response.
* **Maximum Dosing:** Typically not to exceed 4 tablets daily. Specific maximums may vary based on local guidelines and patient tolerance.
## Pediatric Dosing
* There is insufficient data to recommend flupentixol and melitracen for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** Dose reduction may be necessary. Use with caution and monitor closely.
* **Renal Impairment:** No specific dose adjustment guidelines are established, but caution is advised.
* **Elderly Patients:** Often require lower doses due to increased sensitivity to side effects. Initiate at the lower end of the dose range and titrate cautiously.
## Contraindications
* Hypersensitivity to flupentixol, melitracen, or any other component of the formulation.
* CNS depression (e.g., acute alcohol intoxication, barbiturate or opioid overdose).
* Circulatory collapse.
* Comatose states.
* Severe liver disease.
* Pheochromocytoma.
* Concurrent use with MAOIs or within 14 days of discontinuing MAOIs.
* Certain cardiovascular conditions including recent myocardial infarction, severe conduction disorders, or uncompensated heart failure, as determined by a healthcare professional.
## Adverse Effects
* **Common:** Sedation, dry mouth, blurred vision, constipation, dizziness, fatigue, headache, tremors, tachycardia, orthostatic hypotension.
* **Less Common/Serious:** Extrapyramidal symptoms (EPS) including akathisia, dystonia, parkinsonism, tardive dyskinesia (especially with long-term use), anticholinergic toxicity (confusion, urinary retention, hyperthermia), ECG changes, potential for seizures, increased suicidal ideation (especially early in treatment), blood dyscrasias, hepatotoxicity.
## Key Drug Interactions
* **MAOIs:** Risk of hypertensive crisis or serotonin syndrome. Avoid concurrent use.
* **CNS Depressants (alcohol, sedatives, hypnotics, opioids):** Additive CNS depressant effects, increasing sedation and risk of respiratory depression.
* **Anticholinergic Agents:** Additive anticholinergic effects, increasing the risk of constipation, urinary retention, dry mouth, blurred vision, and confusion.
* **Adrenergic Agents (e.g., epinephrine, norepinephrine):** Flupentixol can potentiate the pressor response to some adrenergic agents, but may block others.
* **CYP450 Inhibitors/Inducers:** Melitracen is metabolized by CYP2D6 and CYP3A4. Inhibitors may increase melitracen levels, and inducers may decrease them, potentially affecting efficacy and toxicity. Consider interaction with fluvoxamine, fluoxetine, paroxetine, quinidine, cimetidine, ritonavir.
## Monitoring
* **Mental Status:** Assess for improvement in depressive and anxious symptoms, as well as any signs of worsening, increased suicidality, or emergence of psychosis.
* **Neurological:** Monitor for extrapyramidal symptoms (EPS) and tardive dyskinesia.
* **Cardiovascular:** ECG monitoring may be indicated, especially in patients with risk factors or those on higher doses. Monitor blood pressure and heart rate, particularly for orthostatic hypotension.
* **Anticholinergic Effects:** Monitor for dry mouth, blurred vision, constipation, urinary retention, and cognitive impairment.
* **Hepatic Function:** Periodic monitoring may be warranted, particularly with prolonged therapy or in patients with risk factors for liver disease.
## Clinical Pearls
* This combination is often initiated at a lower dose and titrated upwards based on patient response and tolerance.
* Sedation is a common side effect; administration at bedtime may be preferred for some patients, though the recommended dosing is typically morning and noon.
* Patients starting antidepressant therapy should be monitored closely for emergent suicidality, especially during the initial stages of treatment.
* Anticholinergic side effects can be significant; advise patients on management strategies (e.g., sugar-free candy for dry mouth, stool softeners for constipation).
* Abrupt discontinuation should be avoided due to potential withdrawal symptoms. Tapering the dose is recommended.
***
**Disclaimer:** This information is intended for healthcare professionals and is a summary. It is essential to consult the most current prescribing information and institutional protocols for definitive guidance before initiating or adjusting therapy.
